CXCL8 and metastatic neoplasm: Furthermore, in patients with advanced metastatic tumours, treatment with an anti-IL-8 mAb such as BMS-986253 s (NCT02536469), plus an anti-PDL-1 induced a significant reduction of CXCL8 serum levels and increased anti-tumor activity (NCT03400332).